| Recruiting | Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and M NCT06391099 | Ohio State University Comprehensive Cancer Center | N/A |
| Recruiting | Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial NCT07155317 | Emory University | Phase 2 |
| Withdrawn | Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the NCT05717140 | Mayo Clinic | Phase 1 |
| Recruiting | Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable NCT05896839 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Recruiting | Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected NCT06265285 | Mayo Clinic | Phase 2 |
| Unknown | Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment NCT06151847 | University of Kansas Medical Center | Phase 2 |
| Recruiting | The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor C NCT05967533 | University of California, Davis | Phase 1 |
| Suspended | Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 In NCT05764395 | Vanderbilt-Ingram Cancer Center | Phase 2 |
| Recruiting | Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Met NCT05588453 | Kari Kendra | Phase 1 / Phase 2 |
| Recruiting | BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Mel NCT05136196 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic NCT05388877 | Mayo Clinic | Phase 1 |
| Active Not Recruiting | Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Bra NCT05341349 | Emory University | Phase 1 |
| Recruiting | Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positiv NCT05098210 | Fred Hutchinson Cancer Center | Phase 1 |
| Recruiting | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Soli NCT05269381 | Mayo Clinic | Phase 1 / Phase 2 |
| Recruiting | Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases NCT05026983 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced NCT04514484 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma NCT04697576 | Carlo Contreras | Phase 1 |
| Active Not Recruiting | Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or NCT04940299 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma NCT04967196 | Mayo Clinic | Phase 1 |
| Recruiting | IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors NCT05039801 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) NCT04557956 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | 7T MRI Scan for the Early Detection of Melanoma Brain Metastases NCT04941430 | University of Southern California | N/A |
| Terminated | Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma NCT04527549 | ECOG-ACRIN Cancer Research Group | Phase 2 |
| Terminated | Bone Loss in Melanoma Survivors Receiving Immunotherapy NCT04516122 | M.D. Anderson Cancer Center | — |
| Terminated | Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progress NCT04902040 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer NCT03819296 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | 18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases NCT04752267 | University of Southern California | EARLY_Phase 1 |
| Active Not Recruiting | Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV NCT04462406 | ECOG-ACRIN Cancer Research Group | Phase 2 |
| Terminated | Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases NCT04789668 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab i NCT04511013 | SWOG Cancer Research Network | Phase 2 |
| Terminated | Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype NCT04375527 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Active Not Recruiting | Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With M NCT04645680 | M.D. Anderson Cancer Center | Phase 2 |
| Unknown | Endostar Plus Toripalimab as Adjuvant Therapy for Resectable Stage III-Oligometastatic Stage IV Cutaneous Mela NCT05907512 | Fudan University | Phase 2 |
| Active Not Recruiting | Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors NCT04007744 | Mayo Clinic | Phase 1 |
| Completed | The Effect of the Microbiome on Immune Checkpoint Inhibitor Response in Melanoma Patients NCT05102773 | Ohio State University Comprehensive Cancer Center | — |
| Active Not Recruiting | Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or M NCT03816332 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma NCT03727789 | Roswell Park Cancer Institute | Phase 1 |
| Terminated | Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma NCT03865212 | Mayo Clinic | Phase 1 |
| Completed | Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer NCT04067960 | Mayo Clinic | EARLY_Phase 1 |
| Completed | Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain NCT03873818 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and Aft NCT03698019 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease NCT03025256 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melano NCT03033576 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY NCT02650986 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |
| Active Not Recruiting | Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Me NCT03175432 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medication NCT02595866 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizuma NCT02506153 | National Cancer Institute (NCI) | Phase 3 |
| Active Not Recruiting | Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafe NCT02224781 | National Cancer Institute (NCI) | Phase 3 |
| Terminated | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherap NCT02419495 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types NCT06075524 | Mayo Clinic | — |
| Active Not Recruiting | Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer NCT02298959 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mut NCT01989585 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cance NCT02020707 | Mayo Clinic | Phase 1 |
| Completed | Ipilimumab and Imatinib Mesylate in Advanced Cancer NCT01738139 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Stereotactic Radiosurgery in Treating Patients With Greater Than 3 Melanoma Brain Metastases NCT01644591 | M.D. Anderson Cancer Center | Phase 2 |